|
Lung Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
MET exon 14 alterations, which result in increased MET protein levels due to disrupted ubiquitin-mediated degradation, occur at a prevalence of around 3% in adenocarcinomas and around 2% in other lung neoplasms, making them attractive targets for the treatment of lung cancer.
|
28024693 |
2017 |
|
Lung Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Almost four-fifths of the lung tumors with MET exon 14 skipping had EGFR and/or HER2 gene copy number gains.
|
27223439 |
2016 |
|
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
High-MET status in non-small cell lung tumors correlates with receptor phosphorylation but not with the serum level of soluble form.
|
27794409 |
2016 |
|
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
KRAS coding exons in 61 treatment-naive colorectal cancer (CRC) tumors and KRAS, EGFR, ALK, and MET in lung tumors from three Chinese non-small cell lung cancer (NSCLC) patients were sequenced using ultradeep sequencing methods.
|
24200637 |
2014 |
|
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Amplification of MET has been reported in approximately 5%-22% of lung tumors with acquired resistance to small-molecule inhibitors of the epidermal growth factor receptor (EGFR).
|
23345546 |
2013 |
|
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.
|
20934974 |
2010 |
|
Lung Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.
|
19139719 |
2009 |
|
Lung Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
|
19096300 |
2009 |
|
Lung Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Unlike the frequently encountered somatic mutations in EGFR, MET mutations in lung tumors were germline.
|
19723643 |
2009 |
|
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MET and stem cell factor (SCF) were found to be positively stained in the bronchioalevolar junctions of lung tumors.
|
18709663 |
2008 |
|
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer.
|
19037978 |
2008 |
|
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
|
18379349 |
2008 |
|
Lung Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
|
18093943 |
2007 |
|
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.
|
17332337 |
2007 |
|
Lung Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
|
17463250 |
2007 |
|
Lung Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The treatment of lung tumors with c-Met antisense versus U6 control plasmid resulted in the downregulation of the c-Met protein expression, a 50% decrease in tumor growth over a 5-week treatment period and an increased rate of apoptosis.
|
14737093 |
2004 |